Innovative Drug Development: Balancing Efficacy and Toxicity in Novel Pharmaceuticals

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Pharmaceutical Science".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 500

Special Issue Editor


E-Mail Website
Guest Editor
1. Toxicology, Drug Industry, Management and Legislation University Clinic, Faculty of Pharmacy, ”Victor Babeș” University of Medicine and Pharmacy, Timișoara, Romania
2. Research Center for Pharmaco-Toxicological Evaluations, Faculty of Pharmacy, ”Victor Babeș” University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania
Interests: bioactive natural compounds; drug derivatives; cancer research; targeted drug delivery; (nano)pharmaceuticals; in vitro toxicology

Special Issue Information

Dear Colleagues,

Drug development remains a complex and ongoing process leading to innovative medicines that address unmet medical needs. Despite recent advances, significant challenges such as limited efficiency, drug resistance, a lack of targeted action, or severe adverse reactions persist, hastening research on optimized therapeutics with a favorable risk–benefit profile. To overcome these obstacles and balance efficacy against toxicity, several strategies have emerged. These include the discovery of new pharmacologically active agents that target specific disease pathways, providing enhanced therapeutic properties and reduced toxic events, as well as the formulation of advanced drug delivery systems that enable the targeted transfer of the delivered agents, increasing their biological activity while minimizing side effects. This Special Issue invites innovative contributions to the development of novel pharmaceuticals with diverse applications through the obtainment, characterization, and rigorous pharmaco-toxicological screening of new active compounds of varied origins (e.g., natural, semisynthetic, or synthetic), as well as modern formulations designed for the targeted delivery of bioactive compounds. Studies that provide an integrated approach, combining both the rational design of novel pharmaceuticals and the mechanistic understanding of their biological activities, are strongly encouraged for submission to this Special Issue.

Dr. Iasmina Marcovici
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug development
  • pharmaceuticals
  • bioactive compounds
  • new drug candidates
  • drug delivery systems
  • pharmaceutical formulations
  • efficacy and toxicity screening

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

23 pages, 4522 KiB  
Article
Betulinic Acid-Loaded Oleogel as a Novel Pharmaceutical Formulation for Potential Cutaneous Applications: Development, Characterization, and Biosafety Profile
by Andreea Smeu, Daliana Minda, Casiana Boru, Lavinia Vlaia, Vicențiu Vlaia, Cristina Adriana Dehelean, Sergio Liga, George Puenea and Daniela Lucia Muntean
Life 2025, 15(6), 954; https://doi.org/10.3390/life15060954 - 13 Jun 2025
Viewed by 338
Abstract
Skin disorders constitute a persistent health problem, covering both acute and chronic conditions that manifest in patients of all ages. Betulinic acid (BA) is a triterpene previously studied as an efficient treatment of skin ailments due to its innate pharmacological properties. Nonetheless, due [...] Read more.
Skin disorders constitute a persistent health problem, covering both acute and chronic conditions that manifest in patients of all ages. Betulinic acid (BA) is a triterpene previously studied as an efficient treatment of skin ailments due to its innate pharmacological properties. Nonetheless, due to its lipophilic nature and low bioavailability, topical delivery systems are necessary for its proper administration. Oleogels are efficient carriers for the incorporation of hydrophobic biomolecules; however, their use for the delivery of BA remains scarce. Therefore, this study was designed to develop, characterize, and evaluate a BA-containing oleogel (BA-O) regarding its cutaneous safety profile as a potential pharmaceutical formulation targeting dermatologic issues. The findings illustrated the efficient formulation of BA as oleogel, the product presenting the specific conditions of topical semi-solid formulations in terms of physico-chemical characteristics and high biocompatibility in vitro and in ovo, as BA-O lacked a cytotoxic effect in HaCaT and JB6 Cl 41-5a skin cells (cell viability percentages being > 70%) and was categorized as non-irritant in EpiDerm™ tissues (viability > 80%) and on the chorioallantoic membrane (Irritation Score = 0.186). These results present the preclinical biosafety profile of BA-O with prospective potential for cutaneous applications that should be investigated in future studies. Full article
Show Figures

Figure 1

Back to TopTop